



(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
A61P 35/00 (2006.01) **A61K 47/60** (2017.01)
A61K 31/496 (2006.01)

(48) Corrigendum issued on:
09.02.2022 Bulletin 2022/06

(86) International application number:
PCT/JP2020/027805

(43) Date of publication:
29.12.2021 Bulletin 2021/52

(87) International publication number:
WO 2021/229832 (18.11.2021 Gazette 2021/46)

(21) Application number: **20861942.9**

(22) Date of filing: **17.07.2020**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(72) Inventors:
• **ESHIMA, Kiyoshi**
Tokushima-shi, Tokushima 771-0116 (JP)
• **ISHIDA, Tatsuhiro**
Tokushima-shi, Tokushima 770-0806 (JP)

(30) Priority: **14.05.2020 JP 2020084919**

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(71) Applicant: **Delta-Fly Pharma, Inc.**
Tokushima-shi
Tokushima 771-0116 (JP)

(54) **WATER-SOLUBLE POLYMERIC DERIVATIVE OF VENETOCLAX**

(57) The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.

FIG. 5

